Immunic previously executed a formal corporate reverse stock split at a ratio of 1-for-10, which became effective on April 27, 2026, to satisfy Nasdaq minimum bid price compliance rules and fulfill contractual funding obligations. Future decisions regarding additional stock splits rest entirely with the board of directors and require shareholder authorization based on prevailing market conditions, share price performance, and exchange listing maintenance requirements. Official proxy statements and corporate disclosures provide transparency if any further capital restructuring actions are proposed.